A First-line treatment | A1 Patients unsuitable for | |
(n = 36, 51.4%) | SCT/high-dose chemotherapy (n = 6, 8.6%) | |
all obtained novel agent based therapy | ||
A2 Patients qualifying for | A2a High-dose chemotherapy with | |
transplant based concept (n=30, 42.8%) | autologous SCT (n = 9, 12.9%) | |
A2b High-dose chemotherapy with | ||
tandem-SCT (n = 21, 30.0%) | ||
auto/auto (n = 18, 25.7%) | ||
auto/allo (n = 3, 4.3%) | ||
A2c High-dose chemotherapy with | ||
allogeneic SCT (n = 0) | ||
B Higher treatment line | B1 Patients unsuitable for | |
(n = 34, 48.6%) | SCT/high-dose chemotherapy (n = 18, 25.7%), | |
all obtained novel agent based therapy | ||
B2 Patients qualifying for | B2a High-dose chemotherapy with | |
transplant based concept (n = 16, 22.9%) | autologous SCT (n = 8, 11.4%) | |
B2b High-dose chemotherapy with | ||
tandem-SCT (n = 4, 5.7%) | ||
auto/auto (n = 3, 4.3%) | ||
auto/allo (n = 1, 1.4%) | ||
B2c High-dose chemotherapy with | ||
allogeneic SCT (n = 4, 5.7%) |